NPC1 and metabolic syndrome: Furthermore, NPC1 is the pharmacological target of ezetimibe, which is an inhibitor of cholesterol endocytosis that is widely used for treatment of this dyslipidemia [79]; its inhibition of α-tocopherol absorption [80] suggests the involvement of NPC1 in dietary VE uptake.